CJC-1295 vs CJC-1295 with DAC: Pulsatile vs Sustained GH Release Compared

CJC-1295 and CJC-1295 with DAC are both DPP-IV-resistant synthetic analogs of growth hormone releasing hormone (GHRH), sharing an identical four-substitution peptide core that binds and activates the same pituitary GHRH receptor (GHRHR). The defining difference is pharmacokinetic: the Drug Affinity Complex (DAC) appended to the latter covalently binds serum albumin after injection, extending the effective half-life from roughly 30 minutes to approximately 6-8 days and converting discrete GH pulses into sustained, continuous GH elevation. Choosing between them is a choice between pulsatile physiology and tonic stimulation, with downstream consequences for GH pattern, somatostatin feedback, combination protocols, and the kind of research questions each variant can address.

Key Differentiators at a Glance

Mechanism Side by Side

CJC-1295 (no DAC): DPP-IV-Resistant Pulsatile GHRH Agonism

CJC-1295 without DAC, also called Mod GRF 1-29, retains the 29-amino acid length of native GHRH but incorporates four amino acid substitutions at positions 2, 8, 15, and 27. The substitution at position 2 (Ala to D-Ala or Aib) blocks the primary DPP-IV cleavage site; the remaining substitutions stabilize the helical conformation and reduce susceptibility to other serum proteases. These modifications do not alter GHRHR binding affinity. After subcutaneous injection, the peptide is absorbed rapidly, enters systemic circulation, and reaches anterior pituitary somatotrophs via the hypothalamo-pituitary portal system. There it activates GHRHR with full agonist activity: Gs-coupled adenylyl cyclase activation, cAMP accumulation, PKA-mediated CREB phosphorylation, and GH1 gene transcription.

The effective plasma window of roughly 30 minutes is long enough to elicit a robust GH pulse, but short enough that somatostatin-mediated feedback has time to re-establish before the next injection. This preserves the ultradian GH rhythm that characterizes normal somatotroph physiology. The result is amplified pulsatile GH output, not tonic GH elevation, and each injection event can be designed as a discrete pharmacological pulse.

flowchart TD
    A["CJC-1295 (no DAC) SC injection"] --> B["Rapid absorption\nno albumin binding"]
    B --> C["DPP-IV resistant\n~30 min plasma window"]
    C --> D["GHRHR binding\nanterior pituitary somatotrophs"]
    D --> E["Gs → cAMP → PKA → CREB"]
    E --> F["GH1 transcription\nGH synthesis + exocytosis"]
    F --> G["Discrete GH pulse\nIGF-1 transient elevation"]
    G --> H["Somatostatin feedback\nre-establishes between pulses"]
    H --> I["Physiological pulsatile\nGH rhythm preserved"]

CJC-1295 with DAC: Albumin-Mediated Sustained GHRH Agonism

CJC-1295 DAC shares the same four-substitution peptide core but carries an additional maleimide-based Drug Affinity Complex at the C-terminus. After subcutaneous injection and absorption into systemic circulation, the maleimide group reacts with the free thiol of Cys-34 on serum albumin, forming a stable covalent bond. Albumin’s long biological half-life (approximately 19 days in humans) then acts as a circulating reservoir from which the active GHRH peptide is slowly released. The measured plasma half-life of CJC-1295 DAC was approximately 6.8 days in the Phase 1/2 ConjuChem trial (PMID: 17635940), consistent with slow, albumin-governed dissociation kinetics rather than direct peptide clearance.

The consequence of this sustained release is continuous GHRHR occupancy across days after a single injection. GH synthesis and secretion remain tonically elevated rather than pulsatile, and the physiological somatostatin feedback oscillation that normally produces GH troughs is progressively overridden. IGF-1 elevation measured in PMID: 17635940 persisted for 9-11 days after a single injection of the higher doses studied. This sustained IGF-1 profile is pharmacologically distinct from the brief IGF-1 elevations following no-DAC injections and has different implications for downstream anabolic and metabolic signaling.

flowchart TD
    A["CJC-1295 DAC SC injection"] --> B["Absorption into circulation"]
    B --> C["Maleimide reacts with\nAlbumin Cys-34\ncovalent bond formed"]
    C --> D["Albumin-peptide reservoir\n~6-8 day half-life"]
    D --> E["Slow peptide release\nfrom albumin"]
    E --> F["Continuous GHRHR binding\nanterior pituitary somatotrophs"]
    F --> G["Sustained Gs → cAMP → PKA → CREB"]
    G --> H["Continuous GH synthesis\nand secretion"]
    H --> I["Tonic IGF-1 elevation\n9-11 days per dose"]
    H --> J["Somatostatin feedback\nblunted; pulsatility lost"]

Evidence Strength

Human Pharmacokinetic Evidence: CJC-1295 DAC

CJC-1295 DAC has the stronger direct human evidence base of the two variants. The pivotal study (PMID: 17635940) was a randomized, double-blind, placebo-controlled Phase 1/2 dose-escalation trial conducted by ConjuChem Biotechnologies in 66 healthy adults and GH-deficient patients. Doses ranging from 30 to 120 micrograms per kilogram were evaluated. The study documented dose-dependent increases in mean 24-hour GH concentration, sustained IGF-1 elevation (approximately 30-70% above baseline across the dose range, persisting 9-11 days), and a geometric mean half-life of 6.8 days. No serious adverse events were attributed to the study compound. This controlled trial provides mechanistic and pharmacokinetic characterization at a level of evidence that the no-DAC variant lacks.

Downstream human evidence is thinner. CJC-1295 DAC was not taken into Phase 3 trials or submitted for FDA approval; ConjuChem’s clinical program did not advance to regulatory submission. Post-trial data on long-term IGF-1 maintenance, body composition, or metabolic outcomes in humans are not available from the controlled trial record.

Extrapolated Evidence: CJC-1295 (no DAC)

The no-DAC variant is the form most commonly used in contemporary research-context peptide protocols, yet its controlled human pharmacokinetic literature is limited. The 30-minute effective half-life estimate is derived from understanding of the DAC mechanism (removing the albumin-binding moiety restores short clearance), from DPP-IV inhibition kinetics established in preclinical assays, and from mechanistic extrapolation of the Sermorelin and native GHRH pharmacokinetic literature. There is no published controlled Phase 1/2 trial characterizing the no-DAC variant’s plasma concentration-time profile in humans with the rigor of PMID: 17635940.

The practical evidence base, research-context use, and the broader GHRH receptor pharmacology literature (which includes Sermorelin’s FDA pivotal trials and decades of clinical experience) provide reasonable mechanistic confidence. However, researchers citing primary human evidence for the no-DAC form should note that the best available direct human PK trial studied the DAC variant, not the no-DAC peptide.

Safety Profile Differences

Both variants share the same peptide core, the same receptor target, and the same downstream GH-IGF-1 signaling. Short-term adverse effects reported in PMID: 17635940 for the DAC variant included injection-site reactions (erythema, pain, transient induration), facial flushing and warmth, and mild headache; rates were consistent with GHRH-class peptides and did not differ significantly from placebo for most outcomes at lower doses. The no-DAC variant is expected to share this profile based on mechanism, and observed effects in research-context use (transient flushing, mild water retention, brief paresthesia) are consistent with that prediction.

The meaningful safety distinction is duration of GH and IGF-1 elevation.

CJC-1295 (no DAC): Each injection produces a GH pulse of 2-4 hours’ duration. If GH levels rise excessively for individual physiology, the event resolves within hours and the next injection can be withheld. This provides a natural error-correction interval. Monitoring IGF-1 between injection sessions captures cumulative GH axis activation without the confound of sustained baseline shift.

CJC-1295 DAC: A single injection commits the subject to 7-14 days of elevated GH and IGF-1. If GH rises above the individual’s physiological ceiling, symptoms such as peripheral edema, arthralgia, carpal tunnel syndrome, or glucose intolerance cannot be terminated by withholding further doses; the albumin-bound reservoir continues releasing active peptide until it is exhausted. This persistence makes dose titration more consequential and adverse event management more difficult compared to the short-acting no-DAC form. Researchers working in models where GH axis monitoring is not continuous should account for this difference.

Long-term IGF-1 elevation also carries theoretical oncological considerations given IGF-1’s mitogenic signaling role. Neither variant has long-term safety data in humans; the concern is proportionally greater for the DAC form given its sustained IGF-1 profile.

Neither variant is appropriate for research models studying pituitary insufficiency, where absent somatotroph function would preclude a GH response to GHRHR agonism.

Practical Research-Context Differences

Injection frequency and protocol design. The no-DAC version requires injections at each desired GH pulse event, commonly one to three times daily in research settings. The DAC version is typically administered once or twice weekly; its once-weekly injection schedule represents an operational convenience advantage in long-duration studies or clinical translation contexts. However, that convenience comes with the loss of the ability to titrate within a week.

GH pulse architecture studies. When the research question involves characterizing GH pulse amplitude, frequency, or the interaction between GHRHR and ghrelin receptor (GHSR-1a) signaling, the no-DAC form is the appropriate tool. It generates clean, discrete GH pulses amenable to time-series analysis. The DAC form produces a tonic GH baseline that confounds pulse amplitude measurements and complicates GHRP combination studies where isolated pulse responses are of interest.

IGF-1 maintenance studies. When the research question involves sustained IGF-1 elevation and its downstream anabolic or metabolic consequences, the DAC form is mechanistically better suited. Its 9-11 day IGF-1 elevation window from a single injection allows assessment of sustained signaling effects without requiring daily injections.

Combination with GHRPs. Both forms are used in combination with GHRP-class peptides such as Ipamorelin. With the no-DAC form, each GHRP injection is paired with a no-DAC injection; both signals arrive together, activate complementary receptors (GHRHR and GHSR-1a), and generate a synergistic GH pulse documented at 3-5 times the output of either peptide alone. With the DAC form, the GHRHR signal is continuously present; GHRP administration at any point during the week activates GHSR-1a against a tonically primed GHRHR background rather than generating a synchronized dual-receptor pulse. The pharmacological interaction is materially different, and the 3-5x synergy factor established for the discrete combination may not translate directly.

Research model selection. In vitro and cell-culture studies of GHRHR pharmacology can use either variant; the DAC group does not meaningfully affect receptor binding in isolated somatotroph preparations. In rodent in vivo studies, the short-half-life no-DAC form is more flexible and easier to titrate. The DAC form has been used in longer-duration rodent studies where weekly dosing is operationally simpler, though direct human pharmacokinetics of albumin binding differ from rodent plasma albumin characteristics.

When Researchers Choose CJC-1295 (no DAC)

The no-DAC form is selected when pulsatile GH physiology is the target or the variable under study. Protocols examining the synergistic interaction between GHRH and GHRP receptor pathways, characterizing GH pulse amplitude and frequency, or investigating physiological somatostatin feedback require a GHRH analog whose action resolves within hours. The no-DAC form is also the practical choice for titration contexts where the investigator needs to adjust effective GH axis activation between injection events based on biomarker feedback (IGF-1, fasting glucose). Its wide research-context use means a larger body of protocol precedent is available compared to the DAC variant. Researchers who require a GHRH analog that mimics the shorter-acting pharmacology of Sermorelin but with greater DPP-IV resistance select the no-DAC form.

When Researchers Choose CJC-1295 with DAC

The DAC form is selected when the research question requires sustained GH and IGF-1 elevation over days from minimal injection events. Studies of prolonged IGF-1-driven anabolic signaling, once-weekly dosing feasibility, or the metabolic consequences of tonic GH elevation are best served by the DAC variant’s pharmacokinetic profile. It is also the form with the best-characterized direct human pharmacokinetic data (PMID: 17635940), which is an advantage when anchoring a research protocol to primary literature. For in vivo studies where frequent injection is operationally burdensome or stressful to the model, the DAC form’s weekly administration interval simplifies protocol execution. Researchers who explicitly wish to study the DAC mechanism itself, or the pharmacological consequences of albumin-binding prodrug strategies applied to peptides, find the DAC form uniquely informative.

Closing

CJC-1295 and CJC-1295 with DAC share a peptide identity at the receptor level; both bind GHRHR with the same affinity and activate the same Gs-cAMP-PKA-CREB cascade in anterior pituitary somatotrophs. The entire downstream divergence flows from a single structural difference: the albumin-reactive maleimide DAC group. That group converts a 30-minute-action pulsatile GHRH analog into a 7-day depot that sustains GH and IGF-1 elevation continuously. The choice between them is therefore a research design decision about GH pattern, not a question of receptor pharmacology.

Neither compound carries FDA approval, and neither should be interpreted as a substitute for physician-supervised endocrine assessment. Research involving GH-axis peptides requires monitoring of IGF-1, fasting glucose, and relevant metabolic markers by qualified investigators. The DAC variant’s multi-day commitment to GH elevation makes baseline monitoring and careful dose selection especially important before initiating any protocol.

For deeper context on the CJC-1295 (no DAC) peptide, see the full research hub:

• CJC-1295 Research Hub

See also

Individual research hubs:

• CJC-1295 research

Related comparisons:

• BPC-157 vs CJC-1295
• CJC-1295 vs Sermorelin
• Hexarelin vs CJC-1295